Want to join the conversation?
$ARNA 2Q15 Call: Revised 2015 outlook: R&D expenses of $103-111MM vs. previous outlook of approx. $114-122MM; the revised outlook includes approx. $13MM in non-cash expenses and $1.4MM in development expenses reimbursed by Eisai, with such reimbursed expenses included in revenue. All other guidance previously given remains unchanged.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.